Optimer Pharmaceuticals LLC clinical trials
Acquired by Merck & Co., Inc, Jan 21, 2015 · source ↗
The registry lists 6 studies whose lead sponsor is Optimer Pharmaceuticals LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 18, 2018.
- 6studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- 6
- First submitted after Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Optimer Pharmaceuticals LLC’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Fidaxomicin3 in phase 30 open · 5
- prulifloxacin1 in phase 30 open · 1
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed6100%
Over the years
- 212
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 4 started before 2012. 2026 so far in the lighter column.
Registry sponsor names on this page
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Merck & Co., Inc studies →
- Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)CompletedNCT01691248Phase 3
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedNCT01591863Phase 2
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedNCT00468728Phase 3
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)CompletedNCT00314951Phase 3
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)CompletedNCT00097422Phase 2
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc
- Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult TravelersCompletedNCT00448422Phase 3
Sponsor listed in the registry: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Optimer Pharmaceuticals LLC became part of Merck & Co., Inc